Plus de 40 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Optimizing a deployable high efficacy malaria vaccine (OptiMalVax)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in ...
Voir le projet
17
Participants partenaires
TERMINÉ
An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2021,
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Voir le projet
43
Participants partenaires
TERMINÉ
Optical Infrared Coordination Network for Astronomy (OPTICON)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
Europe has become a global leader in optical-near infrared astronomy through excellence in space and ground-based experimental and theoretical research. While the major infrastructures are delivered through major national and multi-national agencies (ESO, ESA) their continuing scientific competitiveness requires a strong community of scientists and technologists distributed across Europe’s nations ...
Voir le projet
34
Participants partenaires
TERMINÉ
Characterisation Of A Green Microenvironment And To Study Its Impact Upon Health and Well-Being in The Elderly As A Way Forward For Health Tourism. (CHARMED)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
Our society in Europe is still under prepared for the demographic changing situation of an ageing population which began several decades ago. This is visible in the age structure of the population and is reflected by the fact that the population aged 65 years and over is increasing in every European country. The growth in the elderly population may be explained by increased longevity, but at the s ...
Voir le projet
19
Participants partenaires
TERMINÉ
Boost Brittle Bones Before Birth (BOOSTB4)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe OI is affected throughout their lifetime with repeated, multiple fractures, considerable pain and handicap. There is no curative or effective treatment for OI. Our preclinical studies and initial clinical cases have demonstrated that transplantation of fetal m ...
Voir le projet
13
Participants partenaires
TERMINÉ
Training European Experts in Multilevel Bioimaging, Analysis and Modelling of Vertebrate Development and Disease (ImageInLife)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
This proposal sprang from European scientists in both academia and industry who identified a common challenge: setting up a training frame to educate the next generation of imagers in complex biological systems (healthy & pathological), so they are able to master all major aspects of this competitive field and bring important innovations to universities and companies.The long-term goal of any init ...
Voir le projet
11
Participants partenaires
TERMINÉ
Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen (U-PGx)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and reduction in ‘trial and error’ prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and ...
Voir le projet
16
Participants partenaires
TERMINÉ
New therapies for uveal melanoma (UM Cure 2020)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Uveal melanoma (UM) is a rare intraocular tumour with an incidence of 5 cases per million individuals per year. Up to 50% of UM patients develop metastases, most often in the liver, and these are invariably fatal. Despite new discoveries in the genetic and molecular background of the primary tumour, little is known about the metastatic disease; furthermore, there is no therapy to either prevent or ...
Voir le projet
13
Participants partenaires
TERMINÉ
European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry (EN_ACTI2NG)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
The EN-ACTI2NG program (European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry) emanates from the recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate certain tumors that do not respond to conventional treatment. To obtain T cells with reactivity to a wider array of tumors an ...
Voir le projet
11
Participants partenaires
TERMINÉ
Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)
Date du début: 1 juin 2015, Date de fin: 30 nov. 2020,
The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Voir le projet
25
Participants partenaires
TERMINÉ
Common mechanisms and pathways in Stroke and Alzheimer's disease. (CoSTREAM)
Date du début: 1 déc. 2015, Date de fin: 30 nov. 2020,
Common mechanisms and pathways in Stroke and Alzheimer's disease.It has long been recognized that stroke and (Alzheimer’s Disease) AD often co-occur and have an overlapping pathogenesis. As such, these two diseases are not considered fellow travelers, but rather partners in crime. This multidisciplinary consortium includes epidemiologists, geneticists, radiologists, neurologists with a longstandin ...
Voir le projet
11
Participants partenaires
TERMINÉ
The Extensive and Ubiquitous Role of Polycyclic Aromatic Hydrocarbons (PAHs) in Space (EUROPAH)
Date du début: 1 oct. 2016, Date de fin: 30 sept. 2020,
Large Polycyclic Aromatic Hydrocarbon (PAH) molecules are deeply interwoven in the fabric of the Universe and lock up ~15% of the elemental carbon in the interstellar medium (ISM) of galaxies. They dominate the mid-infrared emission characteristics of galaxies that can be used to trace star formation locally as well as in the early universe, they influence the phase structure of the ISM and the st ...
Voir le projet
9
Participants partenaires
TERMINÉ
Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) (BRIDGES)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention or prophylactic surgery. Breast cancer risk is determined by a combination of genetic and lifestyle risk factors. The advent of next generation sequencing has opened up th ...
Voir le projet
20
Participants partenaires
TERMINÉ
A Clinical Decision Support system based on Quantitative multimodal brain MRI for personalized treatment in neurological and psychiatric disorders (CDS-QUAMRI)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
A large number of neurological and psychiatric disorders lack objective criteria for primary diagnoses, early differential diagnosis with regard to subtypes in treatment response and disease progression or effective therapy monitoring resulting in a tremendous negative socio-economic impact. Scientific studies based on advanced MRI methods indicate that related patients show specific subtle change ...
Voir le projet
7
Participants partenaires
TERMINÉ
Circular European Economy Innovative Training Network (CircEuit)
Date du début: 1 sept. 2016, Date de fin: 31 août 2020,
Circ€uit – the Circular European Economy Innovative Training Network - creates a cohort of future leaders in research, policy & business through its innovative training programme focused on the Circular Economy. Circular business models, based on leasing or providing functionality rather than products, often called Product Services Systems, are widely seen as a way how business can create sustaina ...
Voir le projet
7
Participants partenaires
TERMINÉ
Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)
Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,
Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet
44
Participants partenaires
TERMINÉ
Image-Guided Surgery (IGS) and Personalised Postoperative Immunotherapy To Improving Cancer Outcome (ISPIC)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
The basic concept of our proposal is to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment option for many types of c ...
Voir le projet
14
Participants partenaires
TERMINÉ
DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) (SCIDNET)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for ...
Voir le projet
13
Participants partenaires
TERMINÉ
Tools and TECHNOlogies for Breakthrough in hEArt Therapies (TECHNOBEAT)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Cardiovascular diseases including myocardial infarction (MI), which entails the irreversible loss of heart muscle tissue, constitute a major socio-economic burden in global healthcare. With whole organ transplantation as the only treatment option for end-stage heart failure, MI patients could particularly benefit from advanced cell therapies aimed at the functional reconstitution of damaged hearts ...
Voir le projet
8
Participants partenaires
TERMINÉ
Advanced Regenerative and REStorative Therapies to combat corneal BLINDNESS (ARREST BLINDNESS)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Over 30 million Europeans are blind or visually impaired, leading to reduced quality of life and a tremendous loss of productivity in society. Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medic ...
Voir le projet
14
Participants partenaires
TERMINÉ
Knowledge in the making in the European society (KNOWMAK)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2019,
KNOWMAK project aims at developing a web-based tool, which provides interactive visualisations and state-of-the-art indicators on knowledge co-creation in the European Research Area (ERA). It is structured around three integrative elements:• Research topics, by developing ontologies around Societal Grand Challenges and Key Enabling Technologies.• Actors, with a focus on the quadruple helix and the ...
Voir le projet
7
Participants partenaires
TERMINÉ
MULTIscale SENTINEL land surface information retrieval PLatform (MULTIPLY)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
With the start of the SENTINEL era, an unprecedented amount of Earth Observation (EO) data will become available. Currently there is no consistent but extendible and adaptable framework to integrate observations from different sensors in order to obtain the best possible estimate of the land surface state. MULTIPY proposes a solution to this challenge. The project will develop an efficient and ful ...
Voir le projet
9
Participants partenaires
TERMINÉ
Systems Medicine of Mitochondrial Parkinson’s Disease (SysMedPD)
Date du début: 1 déc. 2015, Date de fin: 30 nov. 2019,
The overall objective of this project is to identify novel drug candidates capable of slowing down the progression of neurodegeneration in the subset of Parkinson’s disease (PD) patients with overt mitochondrial dysfunction. Multi-modal phenotypic characterisation of cohorts of monogenic PD patients with overt mitochondrial dysfunction will be used as an anchor for the discovery of two extreme coh ...
Voir le projet
8
Participants partenaires
TERMINÉ
A training network for the rational design of the next generation of well-defined glycoconjugate vaccines (GLYCOVAX)
Date du début: 1 nov. 2015, Date de fin: 31 oct. 2019,
GLYCOVAX is a network for the education of promising young scientists who will learn how to rationally design a next generation of well-defined and innovative glycoconjugate vaccines to improve current preventive therapies and to tackle unmet medical needs. Glycoconjugate vaccines represent the key for success of vaccination in children. The covalent linkage to proteins renders carbohydrates able ...
Voir le projet
12
Participants partenaires
TERMINÉ
Boosting Engagement of Serbian Universities in Open Science
Date du début: 15 oct. 2016, Date de fin: 14 oct. 2019,
Open science provides an effective framework for the enhancement of research transparency, dissemination, collaborations, and accountability. Serbian academic community have recognized the importance and advantages of open science principles which is manifested through the numerous initiatives undertaken by the government bodies, faculties, libraries, NGOs, and journal publishers. However, in the ...
Voir le projet
11
Participants partenaires
TERMINÉ
EUROPLANET 2020 Research Infrastructure (EPN2020-RI)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
The Europlanet 2020 Research Infrastructure (EPN2020-RI) will address key scientific and technological challenges facing modern planetary science by providing open access to state-of-the-art research data, models and facilities across the European Research Area. Its Transnational Access activities will provide access to world-leading laboratory facilities that simulate conditions found on planetar ...
Voir le projet
35
Participants partenaires
TERMINÉ
Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study (MOGLYNET)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry join their forces for:- creating a common platform of knowledge and language for early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary pharma-skills- exploiting this platform to train a new generati ...
Voir le projet
5
Participants partenaires
TERMINÉ
Aggression in Children: Unraveling gene-environment interplay to inform Treatment and InterventiON strateg (ACTION)
Date du début: 1 juin 2014, Date de fin: 31 mai 2019,
Aggression inflicts a huge personal, psychological and financial burden on affected individuals, their relatives, and society at large. Despite large scientific, preventive, and treatment investments, no decrease in aggressive behavior is seen. This calls for a shift to new approaches. By capitalising on comprehensive longitudinal cohorts, recent advances in genetic, biological, epidemiological, a ...
Voir le projet
12
Participants partenaires
TERMINÉ
MELanoma GENetics - understanding and biomarking the genetic and immunological determinants of melanoma survival (MELGEN)
Date du début: 1 juin 2015, Date de fin: 31 mai 2019,
MELGEN (MELanoma GENetics) – understanding and biomarking the genetic and immunological determinants of melanoma survivalThe MELGEN European Training Network (ETN) will create an environment for long-term, collaborative, inter-sectorial cancer genetics research with the ultimate aim of improving precision (personalised) medicine. In a 2012 report the European Science Foundation identified the impo ...
Voir le projet
7
Participants partenaires
TERMINÉ
EU-STRAT - The EU and Eastern Partnership Countries: An Inside-Out Analysis and Strategic Assessment (EU-STRAT)
Date du début: 1 mai 2016, Date de fin: 30 avr. 2019,
Ten years after its inception, the European Neighbourhood Policy (ENP) has fallen short of accomplishing its mission. The war in Ukraine and the rising tensions with Russia have made a re-assessment of the ENP both more urgent and more challenging. EU-STRAT will address two questions: First, why has the EU fallen short of creating peace, prosperity and stability in its Eastern neighbourhood? Secon ...
Voir le projet
11
Participants partenaires
TERMINÉ
Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,
Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic kidney disease. DKD is associated with greatly increased mortality and frequently progresses to end stage renal failure. Pharmacotherapy, dialysis and transplantation repr ...
Voir le projet
12
Participants partenaires
TERMINÉ
Solutions for CRitical Raw materials - a European Expert Network (SCRREEN)
Date du début: 1 nov. 2016, Date de fin: 30 avr. 2019,
Since the publication of the first list of Critical Raw Materials (CRM) in 2010 by the Ad-hoc Working Group on CRM, numerous European projects have addressed (part of) the CRMs value and several initiatives have contributed to gather (part of) the related community into clusters and associations. This led to the production of important knowledge, unfortunately disseminated. Numerous databases have ...
Voir le projet
30
Participants partenaires
TERMINÉ
Big Picnic:Big Questions - engaging the public with Responsible Research and Innovation on FoodSecurity (BigPicnic)
Date du début: 1 mai 2016, Date de fin: 30 avr. 2019,
Ensuring the availability of and access to sufficient safe and nutritious food is a key priority that impacts all EU citizens and Horizon 2020 has therefore identified food security as one of the major challenges to be addressed. BGCI, an international network organisation will work with botanic gardens, experienced informal science centres with research expertise in food and food plants, alongsid ...
Voir le projet
20
Participants partenaires
TERMINÉ
Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes (DIABIL-2)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2019,
ConceptThe discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.Backgro ...
Voir le projet
7
Participants partenaires
TERMINÉ
European Training Network on Antiviral Drug Development (ANTIVIRALS)
Date du début: 1 mars 2015, Date de fin: 28 févr. 2019,
Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other impor ...
Voir le projet
12
Participants partenaires
TERMINÉ
Advancing the European Multilingual Experience (ATHEME)
Date du début: 1 mars 2014, Date de fin: 28 févr. 2019,
"The project Advancing The European Multilingual Experience (AThEME) takes an integrated approach towards the study of multilingualism in Europe by incorporating and combining linguistic, cognitive and sociological perspectives; by studying multilingualism in Europe at three different levels of societal magnitude, viz. the individual multilingual citizen, the multilingual group, and the multilingu ...
Voir le projet
18
Participants partenaires
TERMINÉ
DIabetes REsearCh on patient sTratification (DIRECT)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2019,
The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Voir le projet
27
Participants partenaires
TERMINÉ
Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies (DISCHARGE)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,
Coronary artery disease (CAD) is the leading cause of death in high-income countries. Invasive coronary angiography (ICA) is the reference standard for the diagnosis of CAD and allows immediate therapy. However, only 40% of patients undergoing ICA actually have obstructive CAD and ICA has relatively rare but considerable risks. Coronary computed tomography (CT) is the most accurate diagnostic test ...
Voir le projet
38
Participants partenaires
TERMINÉ
Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells (IMMUNOSHAPE)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
IMMUNOSHAPE aims at training a new generation of scientists that will be capable of combining state of the art synthesis and screening technology to develop new lead structures for highly selective glycan based multivalent immunotherapeutics for the treatment of cancer, autoimmune diseases and allergy. To this end, we have set up a training program in a unique academic-industrial environment that ...
Voir le projet
17
Participants partenaires
TERMINÉ
TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet